Rifabutin Triple Therapy is Effective in Patients With Multidrug-resistant Strains of Helicobacter pylori
- 1 February 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 52 (2) , 137-140
Abstract
Eradicating Helicobacter pylori continues to be a challenge, and no treatment regimen is uniformly successful in all treated patients. Triple therapy with rifabutin and amoxicillin is a successful rescue therapy after consecutive treatment failures. We designed this study to test the efficacy of 12-day rifabutin-based triple therapy in patients infected with multidrug-resistant strains. Consecutive patients with dyspeptic symptoms after at least 1 antibiotic therapy course for H. pylori infection harboring triple-resistant (clarithromycin, metronidazole, levofloxacin) strains were enrolled. They received triple therapy with esomeprazole 40 mg bid, amoxicillin 1 g bid, and rifabutin 150 mg od for 12 days. Patients who failed rifabutin therapy were treated empirically on the basis of the judgment of the treating physician. A total of 254 out of 756 tested patients were found to be infected with a triple-resistant H. pylori strains after at least 1 antibiotic therapy course. Overall, the infection was eradicated in 213 patients, corresponding to a cure rate of 82.9% (95% CI, 78.3-87.5) by intention-to-treat analysis and 88.7% (95% CI, 84.7-92.7) at per-protocol analysis. In multivariate analysis, no factor was identified as an independent predictor of bacterial eradication. There is no current standard for the growing population of patients with multidrug-resistant strains of H. pylori. The 12-day low-dose rifabutin/high-dose proton pump inhibitor regimen is a safe and reliable option for patients infected with triple-resistant strains.Keywords
This publication has 17 references indexed in Scilit:
- Kyoto global consensus report onHelicobacter pylorigastritisGut, 2015
- Rifabutin‐based High‐dose Proton‐pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment for Helicobacter pyloriHelicobacter, 2014
- Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapyBMJ, 2013
- Culture-based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for Helicobacter pylori InfectionClinical Gastroenterology and Hepatology, 2013
- Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus ReportGut, 2012
- Helicobacter pyloritherapy: Present and futureWorld Journal of Gastrointestinal Pharmacology and Therapeutics, 2012
- Review article: rifabutin in the treatment of refractoryHelicobacter pyloriinfectionAlimentary Pharmacology & Therapeutics, 2011
- OLGA staging for gastritis: A tutorialDigestive and Liver Disease, 2008
- Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 2006
- Severe neutropenia caused by recommended prophylactic doses of rifabutinThe Lancet, 1996